A high-throughput cell-free assay for the evaluation of SARS-CoV-2 neutralizing antibodies
This article was originally published here
N Biotechnol. October 7, 2021: S1871-6784 (21) 00091-1. doi: 10.1016 / j.nbt.2021.10.002. Online ahead of print.
Highly accurate serological tests are essential to assess the prevalence of SARS-CoV-2 antibodies and the level of immunity in the population. This is important for predicting the current and future state of the pandemic. With the recent emergence of new, more infectious variants of SARS-CoV-2, tests for high-throughput analysis of antibodies capable of neutralizing SARS-CoV-2 are becoming even more important. Here we report the development and validation of a robust and high throughput method, which allows the evaluation of antibodies inhibiting the binding between the SARS-CoV-2 spike protein and the angiotensin-2 converting enzyme ( ACE2). The assay uses recombinantly produced f-tips and ACE2 and is performed in a bead array format, which allows analysis of up to 384 samples in parallel per instrument over seven hours, requiring only one hour of manipulation manual. The method is compared to a microneutralization assay using live SARS-CoV-2 and is found to provide highly correlated data. In addition, a comparison with a serological method that measures all antibodies recognizing the spike protein shows that this type of assessment provides important information about the neutralizing effectiveness of the antibodies, especially for people with low levels of antibodies. . This method can be an important and valuable tool for the large-scale evaluation of antibody-based neutralization, including the neutralization of advanced new variants that may emerge.
IDPM: 34628049 | DOI: 10.1016 / j.nbt.2021.10.002